Evidence map›Paper›PMID 2026421›Full record

ArticleHuman genetics1991

Cytogenetic and molecular characterization of a newly established neuroblastoma cell line LS.

G Rudolph, K Schilbach-Stückle, R Handgretinger, P Kaiser, H Hameister

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Human genetics, 1991. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 33 citations in OpenAlex.

  1. Ganglioside Profiling Uncovers Distinct Patterns in High-Risk Neuroblastoma.International journal of molecular sciences · 2025
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. MYCN is retained in single copy at chromosome 2 band p23-24 during amplification in human neuroblastoma cells.Proceedings of the National Academy of Sciences of the United States of America · 1994
    Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

G RudolphAbteilung Klinische Genetik, Universität, Tübingen, Federal Republic of Germany.
K Schilbach-Stückle
R Handgretinger
P Kaiser
H Hameister
Praxis für Humangenetik Tübingen · DEUniversitätskinderklinik · DEUniversität Ulm · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A new human neuroblastoma cell line (LS) that originated from an abdominal tumor of a 16-month-old girl is presented; it was classified, according to Evans, as being stage III. Morphological (dense-core particles) and biochemical characteristics (dopamine-beta-hydroxylase, acetylcholinesterase, neuron-specific-enolase) confirmed the diagnosis. In addition to a slightly variable modal chromosome number of 48 or 49 (because of marker-chromosomes and autosomal trisomies), cytogenetic analysis revealed two constantly appearing chromosomes with homogeneously stained regions (HSR's). The karyotype remained constant over 50 passages in vitro [49,XX, -12, +der5, + 17, + mar1, + mar2]. Double minutes were a rare phenomenon and appeared only in a few metaphases. In situ hybridization showed that some of the HSR's consisted of amplified N-myc copies. The distribution of the N-myc copies according to in situ hybridization signals along the HSR's was compared with the data of Southern and Northern blotting analyses.

Indexed as

Tumor Cells, CulturedAbdominal NeoplasmsBlotting, NorthernBlotting, SouthernChromosomes, Human, Pair 17DNA, NeoplasmFemaleGene AmplificationGenes, mycHumansInfantKaryotypingNeuroblastomaTrisomyDNA, Neoplasm

Identifiers

PMID2026421
OpenAlexW1982346349

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.